We are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...

There are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...

After the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...

Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...

Pfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...

Venus Remedies has received approval in Argentina for its antibiotic Ceftriaxone. This marks a significant step in the company's Latin Amer...

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

Quadria Capital is eyeing a strategic acquisition of a majority interest in Samarth Lifesciences, a move that could value the transaction a...

Mankind Pharma, guided by Ramesh and Rajeev Juneja, is a leading Indian pharmaceutical firm. The company focuses on mass-market drugs and h...

The other leading molecules in the same segment, like rosuvastatin and telmisartan, continued to grow in line with the therapy segment, the...

Monsoon led to a surge in demand for respiratory, anti-infective, and anti-malarial products. The respiratory market saw a notable increase...

Sheetal Sapale, VP, commercial, Pharmarack, said four key therapy segments - cardiac, anti-infectives, gastro and respiratory - have driven...

The onset of the monsoon in June led to a significant increase in sales of drugs for respiratory, anti-infective, anti-malaria, and gastroi...

India's pharma market took a dip in March after poor sales of respiratory and anti-infective therapies dropped post-winter. April saw the m...

India's pharmaceutical market witnessed a robust 9% month-on-month growth in February, driven by strong performance in cardiology and anti-...

The Indian pharmaceutical market (IPM) saw a robust growth of 9.5% in January with all major therapy areas recording double-digit growth. A...

In a grim reminder of the rise of lifestyle diseases, anti-diabetic molecule has for the first time become the largest-selling formulation ...